Article | May 9, 2024

Data Intelligence Requires An Intelligent, Data-Driven Approach To Digital Transformation

Source: IDBS UK HQ

By Unjulie Bhanot, Product Marketing Manager (Process Development & Manufacturing), IDBS

Digital technology-GettyImages-826921436

Digital tools like artificial intelligence (AI) and machine learning (ML) are being adopted into more areas of the BioPharma industry to speed up drug discovery and reduce development costs. However, this digitalization adds complexity to regulatory decision-making. To overcome these challenges, companies are working to ensure their data is complete, accessible, high-quality, and systematically managed. Regulatory authorities like the European Medicines Agency and the EU Heads of Medicines Agencies have published guidelines for using AI-generated data for quality decision-making. Despite the challenges, the potential benefits of AI and ML in the BioPharma industry are significant, with estimates suggesting the technology could generate $60 billion to $110 billion a year in economic value for the pharma and medical-product industries.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online